ApoB siRNA therapy (Sirna/Merck & Co)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameApoB siRNA therapy (Sirna/Merck & Co)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApolipoprotein B-100 inhibitors
TargetsApolipoprotein B-100
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSirna Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSirna Therapeutics IncMerck & Co Inc
Active IndicationsN/A
Inactive IndicationsHypercholesterolemia

Other Information

ATC CodeN/A
Related LinksN/A